The INPP5B Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population engineered to disrupt the INPP5B gene within the A-549 human lung adenocarcinoma cell line. This population comprises a heterogeneous mix of cells carrying CRISPR-mediated loss-of-function mutations in INPP5B, generating a versatile tool for examining the functional consequences of INPP5B deficiency. As a polyclonal knockout model, it avoids clonal selection artifacts and provides a broader representation of genetic heterogeneity, which is particularly relevant for cancer biology research.
The parental A-549 cell line is a widely utilized in vitro model of non-small cell lung cancer (NSCLC), originally established from a lung adenocarcinoma of a 58-year-old Caucasian male. These malignant epithelial cells grow as an adherent monolayer and retain wild-type TP53, along with an activating KRAS G12S mutation, mirroring common oncogenic drivers in lung adenocarcinoma. A-549 cells are instrumental in studying EGFR signaling, apoptotic pathways, and tumor metastasis, thus offering a clinically relevant backdrop for gene knockout studies.
INPP5B encodes a phosphoinositide 5-phosphatase that specifically hydrolyzes the D5-phosphate from phosphatidylinositol (3,4,5)-trisphosphate (PIP3) to generate PI(3,4)P2, thereby terminating PI3K-dependent AKT activation. In the signaling cascade, INPP5B functions as a negative regulator downstream of receptor tyrosine kinases and TP53-dependent stress responses. It interacts with clathrin and the adaptor protein AP2M1 to localize to endocytic membranes, and it complexes with the PI3K regulatory subunit PIK3R1. Disruption of INPP5B leads to unopposed AKT1 phosphorylation at S473, resulting in constitutive activation of downstream effectors including MTOR, ribosomal protein S6 kinase (RPS6KB1), and inhibition of GSK3B and FOXO transcription factors, ultimately promoting cell survival, proliferation, and metabolic reprogramming.
In A-549 cells, INPP5B knockout hyperactivates the PI3K/AKT axis in the context of KRAS-driven oncogenesis, providing a powerful model to study the cooperative signaling between RAS and PI3K pathways. Since sustained AKT activity is a hallmark of therapeutic resistance in NSCLC, these polyclonal knockout cells are particularly valuable for investigating mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors and other targeted agents. Moreover, the loss of INPP5B mimics the PTEN-deficient phenotype commonly observed in lung tumors, allowing researchers to dissect the PI3K pathway dependencies and identify synthetic lethal interactions.
Research applications span from fundamental studies of tumor suppressor mechanisms to translational investigations in drug sensitivity screening. Western blotting for INPP5B and phospho-AKT(S473) confirms knockout effects, while RT-qPCR quantifies INPP5B mRNA levels. Transcriptomic analysis via RNA-seq reveals pathway rewiring, and functional assays such as MTT proliferation, Annexin V apoptosis, and Transwell migration and invasion assays characterize phenotypic outcomes. Drug sensitivity assays using PI3K, AKT, or MTOR inhibitors can evaluate therapeutic vulnerabilities. For further technical specifications or customized services, please contact Ascent Research.
